Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

To compare insulin lispro with soluble human insulin in patients with Type 2 diabetes mellitus fasting during Ramadan, with respect to the rate of hypoglycaemic episodes and postprandial blood glucose values after the main meal after sunset.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

The insulins were compared in an open-label, randomized, cross-over study of 70 outpatients.

Hypoglycaemic episodes were recorded by the patients in a self-monitoring diary.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Being open-label, the Insulin Lispro study did not mask who received what.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

Fasting, 1-h and 2-h postprandial blood glucose values were recorded by the patient on three consecutive days at the end of each treatment period.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Food, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.